论文部分内容阅读
Background LDL-C is primary treatment target for patients with dislipidemia.The apo B,an emerging biomarker for cardiovascular risk prediction,appears to be superior to the LDL-C.However,little is known about goal attainments and their discrepancies for LDL-C and apo B in Chinese patients with known CAD or DM.